Investors bought shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on weakness during trading on Friday. $54.13 million flowed into the stock on the tick-up and $41.41 million flowed out of the stock on the tick-down, for a money net flow of $12.72 million into the stock. Of all stocks tracked, Alexion Pharmaceuticals had the 24th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($1.50) for the day and closed at $125.80

ALXN has been the topic of several analyst reports. Morgan Stanley increased their target price on shares of Alexion Pharmaceuticals from $195.00 to $210.00 in a report on Friday, April 8th. Vetr raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $161.67 price objective for the company in a research report on Monday, April 11th. Brean Capital reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Thursday, April 28th. Piper Jaffray Cos. reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Thursday, April 28th. Finally, Cowen and Company reissued a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, April 17th. Seven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $190.61.

The firm has a 50 day moving average of $126.57 and a 200 day moving average of $141.81. The firm has a market capitalization of $28.18 billion and a price-to-earnings ratio of 190.32.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the Zacks’ consensus estimate of $1.13 by $0.02. The business had revenue of $701 million for the quarter, compared to analyst estimates of $710.98 million. The company’s quarterly revenue was up 16.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.28 EPS. On average, equities analysts expect that Alexion Pharmaceuticals Inc. will post $5.05 earnings per share for the current fiscal year.

In related news, EVP Martin Mackay sold 4,097 shares of the stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $139.20, for a total transaction of $570,302.40. Following the completion of the transaction, the executive vice president now owns 42,706 shares in the company, valued at $5,944,675.20. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP John B. Moriarty sold 918 shares of the stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $135.72, for a total transaction of $124,590.96. Following the transaction, the executive vice president now owns 51,360 shares of the company’s stock, valued at approximately $6,970,579.20. The disclosure for this sale can be found here.

A number of institutional investors recently bought and sold shares of the stock. Principal Financial Group Inc. raised its position in Alexion Pharmaceuticals by 2.3% in the fourth quarter. Principal Financial Group Inc. now owns 316,710 shares of the biopharmaceutical company’s stock valued at $60,412,000 after buying an additional 7,145 shares during the last quarter. Bank of Montreal Can raised its position in Alexion Pharmaceuticals by 46.5% in the fourth quarter. Bank of Montreal Can now owns 230,164 shares of the biopharmaceutical company’s stock valued at $43,902,000 after buying an additional 73,039 shares during the last quarter. Twin Capital Management Inc. raised its position in Alexion Pharmaceuticals by 15.2% in the fourth quarter. Twin Capital Management Inc. now owns 19,310 shares of the biopharmaceutical company’s stock valued at $3,683,000 after buying an additional 2,550 shares during the last quarter. Sawtooth Asset Management Inc. raised its position in Alexion Pharmaceuticals by 15,072.9% in the fourth quarter. Sawtooth Asset Management Inc. now owns 7,283 shares of the biopharmaceutical company’s stock valued at $1,389,000 after buying an additional 7,235 shares during the last quarter. Finally, Mutual of America Capital Management LLC raised its position in Alexion Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 25,147 shares of the biopharmaceutical company’s stock valued at $4,797,000 after buying an additional 118 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.